Filing Flows › Health Care › Skinvisible (SKVI)
Skinvisible (SKVI) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 13, 2026 · Skinvisible (SKVI) Q2 2026 earnings results →
Q2 2026 Revenue up 0% year over year to $5K
Skinvisible made $5K in Q2 2026 (0% Y/Y). Operating margin n/m, net loss $256K. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 13, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $5K in Q2 2026, roughly flat year over year and roughly flat from the previous quarter.
Gross margin was 100.0%, unchanged from Q2 2025. Operating costs exceeded revenue by $113K, an operating margin of -2256.3%. Operating expenses fell 17% while revenue was flat. The quarter ended with a net loss of $256K, narrower than the previous quarter's $267K loss. Net interest and other expense of $143K was the main reason.
Operating cash flow was $2K. Non-cash charges added back $5K of depreciation and amortization. Working capital and other items added $253K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 13, 2026 | $5K | 0% | n/m | −$256K | $2K |
| Q1 2026 | 10-Q | May 13, 2026 | $5K | 0% | n/m | −$267K | −$1K |
| Q4 2025 | 10-K | Mar 31, 2026 | $5K | — | n/m | −$258K | $2K |
| Q3 2025 | 10-Q | Nov 13, 2025 | $5K | 0% | n/m | −$250K | $1K |
| Q2 2025 | 10-Q | Aug 13, 2025 | $5K | 0% | n/m | −$274K | −$9K |
| Q1 2025 | 10-Q | May 14, 2025 | $5K | 0% | n/m | −$281K | −$32K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Skinvisible
We, through our wholly owned subsidiary Skinvisible Pharmaceuticals Inc., are a pharmaceutical research and development (“R&D”) company that has developed and patented an innovative polymer delivery system, Invisicare® and formulated over forty topical skin products, which we out-license globally. We were incorporated in 1998 and target an estimated $80 billion global skincare and dermatology market and a $30 billion global over-the-counter market as well as other healthcare / medical and consumer goods markets. We are also exploring new opportunities in large medical markets outside of the dermatology market such as obesity and other potential markets where a topical or transdermal solution would be a viable alternative.
In its own words, from its 10-K, filed Mar 31, 2026.
Skinvisible against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: 0% against the peers' median +7%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| SKVI Skinvisible | Q2 2026 | $5K | 0% | n/m |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Skinvisible 10-Q on SEC EDGAR · CIK 1085277 · Pharmaceutical Preparations
More on SKVI
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results